Skip to content
Industry
This is research, not advice. We’re not SEBI-registered.

Arvaya Healthcare share price today

ARVAYATrading companyStandalonePrices to 17 Nov 2026Results to Jun 2026

Price, 200-day average and NIFTY 500

The price is 28.3% above its 200-day average and 300 points ahead of the NIFTY 500 over 5 years

17 Nov 2026₹101.65Over 5 years: Arvaya Healthcare +360.0%, NIFTY 500 +60.3%
₹20₹100Nov 22Nov 24Nov 26

Price growth

1Y3Y5Y10Y1Y+113.0%3YToo short5YToo short10YToo short

EPS and P/E

EPS −₹0.94, against ₹0.27 a year earlier; no P/E, as the last four quarters are a loss

17 Nov 2026−₹0.94 EPSNo P/E on 17 Nov 2026: earnings over the last four quarters are a loss
Sep 21
Dec 21
Mar 22
Jun 22
Sep 22
Dec 22
Mar 23
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
₹1−₹1

EPS growth

1Y3Y5Y10Y1YNot meaningful3YNot meaningful5YNot meaningful10YNot meaningful

Revenue and margins

Revenue ₹0 crore; operating margin -810.0%, the lowest on this chart

Jun 2026 quarter₹0 croreNPM -890.0%
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
0₹0
Revenue growth1Y−47.4%
Rev 3Y, Rev 5Y, Rev growth10YNot meaningful
OPM 3Y, OPM 5Y, NPM 3Y, NPM growth5YToo short

Return on capital

ROCE was -3.7% for the year to Mar 2026, down from -2.2% in the year to Mar 2021

Year to Mar 2026-3.7% ROCE
-10%10%Mar 22Mar 24Mar 26

ROCE average

1Y3Y5Y10Y1Y-3.7% to Mar3Y-7.1% to Mar5Y-7.5% to Mar10Y-4.8% to Mar

Profit and cash

Cash from operations was −₹8 crore in the year to Mar 2026, against a loss of ₹1 crore; profit over five years is a loss (−₹2 crore), so cash as a share of profit has no meaning

Yearly profit, cash from operations and free cash flow, ₹ crore

FY26−₹8 crore operating cashFree cash −₹13 crore
FY22
FY23
FY24
FY25
FY26
₹2−₹14

Profit growth

1Y3Y5Y10Y1YNot meaningful3YNot meaningful5YNot meaningful10YNot meaningful

Reinvestment

Capex was ₹5 crore in the year to Mar 2026, with no depreciation to compare

FY26₹5 crore capexWork in progress ₹0 crore
FY22
FY23
FY24
FY25
FY26
0₹6

Capex growth: 1Y change, then growth a year

1Y3Y5Y10Y1YNot meaningful3Y+238.6%/yr to Mar5YNot meaningful10Y+52.2%/yr to Mar

BorrowingsInsufficient history, from Jun 2023Insufficient history, from Jun 2023

Debt ÷ equity 0.04 at 31 Mar 2026; profit before interest was a loss over the last four quarters, so interest was not covered

Mar 2026 balance sheet0.04 debt ÷ equityProfit covers interest -13.2x · Net debt ₹0 crore
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
2.5x-15x

Safety

Now3Y ago
Debt ÷ equity0.043Y ago0.02
Int. cover-13.2x3Y ago-44.0x

Operating health

Working capital fell from 513.98 to 273.75 days in 5 years

Year to Mar 2025273.75 days working capital
0750Mar 21Mar 23Mar 25
Working cap.273.751Y+39.113Y−666.45Y−240.23
Debtor01Y−104.293Y−88.485Y−126.63
Inventory01Y−86.93Y−111.095Y−57.03

OwnershipInsufficient history, from Sep 2023Insufficient history, from Sep 2023

FIIs own 0.00%, up 0.00 points in a year. Promoters hold 30.62%

Share of the company held, %, by quarter end

Sep 2026 quarter0.00% FIIs
0%60%Sep 24Sep 25Sep 26

Change in holding, in points

FIIs1Y0.003Y0.00
Promoters1Y−32.113Y+22.88

Arvaya Healthcare Ltd · ARVAYA · Trading · price as of the 17 November 2026 close, updated every trading day · results updated weekly

Arvaya Healthcare share price today: ₹101.65 at the BSE close on 17 November 2026. Arvaya Healthcare (ARVAYA) is worth ₹488 crore. Latest change: lowest operating margin in 9 quarters.

₹101.65Price
₹0.1 CrRevenue (Jun 2026)
−₹0.9 CrProfit (Jun 2026), incl. one-off one-off item, see below
−810.0%Operating margin

Arvaya Healthcare Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer.

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high.

The price has been rising for 61 weeks. Over the last four quarters, results have been mixed. What will decide it: the next one or two quarters of results.

Figures we could not check: Some figures on this page come from a second data source that we could not check against the main one, because the two do not cover enough of the same periods. They are shown because they are the only figures there are, and every section that uses one is marked unverified.

What is the Arvaya Healthcare share price today?

Arvaya Healthcare Ltd's share price was ₹101.65 at the close on 17 November 2026. It has been rising for 61 weeks. That is 28.3% above its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 4 weeks running.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Arvaya Healthcare Ltd is in stage 2. The phase helps read everything below.

Since its first close in our records, on 24 June 2026, it has traded between ₹67 and ₹142, and at that close it sat 46% of the way up from that low.

Week by week since 2026: did it beat the NIFTY 500 over the past 13 weeks?

Ahead in 3 of 7 weeks

Week by week since 2026: did it beat the NIFTY 500 over the past 13 weeks?
Week13-week return vs NIFTY 500
24 Jun 2026no NIFTY 500 reading
10 Jul 2026no NIFTY 500 reading
17 Jul 2026no NIFTY 500 reading
24 Jul 2026no NIFTY 500 reading
31 Jul 2026no NIFTY 500 reading
7 Aug 2026no NIFTY 500 reading
14 Aug 2026no NIFTY 500 reading
18 Aug 2026no NIFTY 500 reading
11 Sep 2026no NIFTY 500 reading
18 Sep 2026no NIFTY 500 reading
25 Sep 2026no NIFTY 500 reading
1 Oct 2026no NIFTY 500 reading
9 Oct 2026no NIFTY 500 reading
16 Oct 2026+50.9%
23 Oct 2026+28.2%
27 Oct 2026+2.3%
30 Oct 2026−14.3%
8 Nov 2026−18.7%
9 Nov 2026−6.5%
17 Nov 2026−6.5%
Each bar is one week, from 2026 to now (7 weeks with a reading). Green means the stock's return over the previous 13 weeks beat the NIFTY 500; red means it trailed. The colour is strongest at a gap of 25 percentage points or more. A gap means there is no reading for that week.

Over the last 5 months the share price moved +51% while the NIFTY 500 moved +3%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 27 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

What changed at Arvaya Healthcare this quarter?

3 points in one quarter.

  1. Lowest operating margin in 9 quarters

    Operating margin was -810% in the June 2026 quarter.

  2. Promoters cut their stake by 2.3 points in one quarter

    From 30.6% to 28.3% in the October 2026 quarter.

What are Arvaya Healthcare's latest quarterly results?

For April to June 2026 (the quarter ended 30 June 2026), Arvaya Healthcare reported revenue of ₹0.10 crore, and a loss of ₹0.89 crore.

Arvaya Healthcare results: April to June 2026 against a year earlier

Arvaya Healthcare results: April to June 2026 against a year earlier
MeasureApril to June 2026April to June 2025Change
Revenue₹0.10 crore₹0.00 crore—
Profitloss of ₹0.89 croreloss of ₹0.25 crore—
Earnings per share₹−0.19₹−0.33—
Operating margin−810.0%——

The next results, for July to September 2026, were due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). This page shows them once our weekly data update has read them.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

What is the Arvaya Healthcare share price history?

Arvaya Healthcare closed at ₹101.65 on 17 November 2026. Its highest weekly close since June 2026 was ₹139.41 on 24 July 2026.

Arvaya Healthcare share price: then and now

Arvaya Healthcare share price: then and now
WhenCloseChange to 17 Nov 2026
1 week ago · 11 Nov 2026₹111.20−8.6%
1 month ago · 16 Oct 2026₹98.85+2.8%
Earliest and lowest weekly close in our records · 24 Jun 2026₹67.11+51.5%
Highest weekly close since June 2026 · 24 Jul 2026₹139.41−27.1%

Weekly closing prices. Each change is the move from that price to the 17 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

20 weekly closes from 24 June 2026 to 17 November 2026.

What is the latest news on Arvaya Healthcare?

17 Nov 2026: Arvaya Healthcare closed at ₹101.65, down 8.6% on the week and up 2.8% on the month.

What dividend does Arvaya Healthcare pay?

Arvaya Healthcare has paid no dividend on the exchange since its first close in our records (24 June 2026), the start of the period we checked.

No. Arvaya Healthcare Ltd paid out 0% of its profit as dividends in each of its last 11 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the exchange corporate-actions record, read 18 November 2026.

What to watch in Arvaya Healthcare's next results?

When Arvaya Healthcare reports July to September 2026, this is the check that shows whether the story is still on course: Whether the operating margin stays near −810.0%.

  • Whether the operating margin stays near −810.0%. The latest full year's operating margin was the highest on file. Every ratio built on profit looks better at a peak.

Which stock lists is Arvaya Healthcare on?

Arvaya Healthcare is not on any of our India lists this week.

Is Arvaya Healthcare profitable?

Arvaya Healthcare Ltd posted a net loss of ₹0.9 Cr in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY26 year was a loss of ₹1.2 Cr. The Jun 2026 quarter's loss is 890.0% of that quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier lost ₹0.3 Cr. 11 of the last 12 reported quarters were loss-making.

For the full year, FY26 profit was −₹1.2 Cr (−957.1% on the year before).

Read this profit with care: at −₹0.9 Cr it is bigger than the quarter's whole revenue of ₹0.1 Cr. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −810.0% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings.

How much revenue does Arvaya Healthcare make, and is it growing?

Arvaya Healthcare Ltd reported ₹0.1 Cr of revenue in the Jun 2026 quarter. The last full year, FY26, came in at ₹0.0 Cr. The last four reported quarters add to ₹0.1 Cr. A growth rate over several years is not shown, because there are too few years of figures to work one out properly.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹0.0 Cr, −100.0% on the year before.

Is growth speeding up? Revenue over the last 12 months grew −47.4%, against −42.3% a year over the last 8 quarters (rolling over).

How much of every ₹100 of sales does Arvaya Healthcare keep?

Arvaya Healthcare Ltd's operating margin was −810.0% in the Jun 2026 quarter. Its latest full-year margin is the highest it has ever reported. Across 12 years it has been between −185.7% and 8.0%. The latest quarter is below every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −538.6 percentage points on the year while gross margin changed +0.0 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

Is Arvaya Healthcare's profit turning into cash?

Arvaya Healthcare Ltd's cash-flow history is too short to judge how much of its profit turns into cash. In FY26 its operations used ₹7.9 Cr of cash, against −₹1.2 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After ₹0.0 Cr of estimated spending on assets (worked out from the change in fixed assets plus depreciation; no filed figure), free cash was −₹8.0 Cr: it spent more than its operations brought in.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures.

Where does Arvaya Healthcare's cash go?

Arvaya Healthcare Ltd's customer, stock and supplier day counts are not a useful reading on sales this small (₹0.0 Cr in FY26), so no cash-cycle chart is drawn and this section looks at its spending on assets instead. It spent ₹0.0 Cr on assets over the last 3 years.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Spending on assets: ₹0.0 Cr over the last 3 years. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet.

In short: almost nothing is being spent on new assets, so the cash goes on running the business.

What is Arvaya Healthcare's P/E ratio, and how does it compare with its own history?

Arvaya Healthcare Ltd has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

—P/E · earnings negative

Is the Arvaya Healthcare business getting better or worse?

Arvaya Healthcare Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 7 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading.

RisingROCE · latest (year to Mar 2026) −3.7%, range −11.7% to −3.7%

Why it matters: with too little history, we say so rather than guess a direction.

The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

How much does Arvaya Healthcare earn on its capital?

Arvaya Healthcare Ltd earned a ROCE of −4% in FY26. That is up from a low of −12% in FY23. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 50.0% net margin and 0.08× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY25): a 50.0% net margin × 0.08× asset turnover × 1.02× leverage (assets divided by equity) ≈ 4.1% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

Does Arvaya Healthcare have too much debt?

Arvaya Healthcare Ltd had ₹2.5 Cr of borrowings against ₹58.0 Cr of equity in FY26, so its debt is 0.04× its equity. Over 5 years borrowings went from ₹0.0 Cr to ₹2.5 Cr. Over the last 3 of those years it spent ₹0.0 Cr on assets.

Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.

Part of the spending on assets is being paid for with borrowed money.

What is the Arvaya Healthcare shareholding pattern?

Promoters raised their stake in Arvaya Healthcare Ltd by 20.6 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 28.3% of the company. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Why the owners changed: promoters drove it (+20.6 points). They raised their stake step by step.

How far is Arvaya Healthcare from balance-sheet trouble?

For Arvaya Healthcare Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

How does Arvaya Healthcare rank in its industry?

45.3 out of 100, rank 59 of 65 in Trading, with 46% of the evidence available. It is provisional, so it is ranked below companies with full evidence.

Arvaya Healthcare Ltd scores 45.3 out of 100 against the 65 companies it is compared with in Trading, ranking 59. Some evidence is missing, so the score is pulled toward the middle on purpose.

The four parts add up to the total exactly: 19.5 + 3.9 + 10 + 11.9 = 45.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Which companies is Arvaya Healthcare compared with?

Arvaya Healthcare ranks 59 of 65 Trading companies on the 4-Factor Sector Score, with 45.3 out of 100.

  1. 1Shankara Buildpro LtdBUILDPRO · quiet · Most evidence points up · 63% evidence67.9out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 31.4/43.75 · Revenue 30.2% · Profit 38% · Operating margin change 0.3 points · 100% evidenceCapital efficiency 23.2/31.25 · ROCE 39% (year to Mar 2026) · Operating margin 3.4% · 100% evidenceValuation 13.3/25 · P/E 15.5× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 31.4 + 23.2 + 13.3 = 67.9 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.
  2. 2Mangalam Global Enterprise LtdMGEL · breaking out · Most evidence points up · 83% evidence65.9out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 22.4/35 · Revenue 44.2% · Profit 8.2% · Operating margin change 0.7 points · 100% evidenceCapital efficiency 14.8/25 · ROCE 17% (year to Mar 2026) · Operating margin 2.3% · 100% evidenceValuation 10.8/20 · P/E 14.4× · PEG — · 15% evidenceRelative strength 17.9/20 · Strength vs its industry (price vs its 52-week average, weekly) 6.6% · Strength vs NIFTY 500 (same reading) 19.3% · 1 year 13.8% · 100% evidence · 5 of 12 weeks aheadExact sum: 22.4 + 14.8 + 10.8 + 17.9 = 65.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  3. 3Nupur Recyclers LtdNRL · leader · Most evidence points up · 82% evidence65.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 23.0/35 · Revenue 79.3% · Profit 71.5% · Operating margin change 2.9 points · 95% evidenceCapital efficiency 15.0/25 · ROCE 15.1% (year to Mar 2026) · Operating margin 9.9% · 76% evidenceValuation 7.7/20 · P/E 63.7× · PEG — · 50% evidenceRelative strength 19.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 76.1% · Strength vs NIFTY 500 (same reading) 90.2% · 1 year 216.3% · 100% evidence · 12 of 12 weeks aheadExact sum: 23 + 15 + 7.7 + 19.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  4. 4Rashi Peripherals LtdRPTECH · losing its lead · Evidence leans up · 82% evidence64.6out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 27.0/35 · Revenue 51.1% · Profit 93.2% · Operating margin change 1.1 points · 95% evidenceCapital efficiency 15.1/25 · ROCE 17% (year to Mar 2026) · Operating margin 3.6% · 76% evidenceValuation 10.8/20 · P/E 10.7× · PEG — · 50% evidenceRelative strength 11.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 6.2% · Strength vs NIFTY 500 (same reading) 15.3% · 1 year 90.7% · 100% evidence · 9 of 12 weeks aheadExact sum: 27 + 15.1 + 10.8 + 11.7 = 64.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  5. 5Bhatia Communications & Retail (India) Ltdturning · Evidence leans up · 72% evidence63.6out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 23.9/35 · Revenue 55.2% · Profit 72.1% · Operating margin change 1.5 points · 95% evidenceCapital efficiency 18.6/25 · ROCE 21.3% (year to Mar 2026) · Operating margin 5.7% · 95% evidenceValuation 9.3/20 · P/E 25× · PEG — · 50% evidenceRelative strength 11.8/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 39.8% · 1 year — · 25% evidence · 1 of 1 week aheadExact sum: 23.9 + 18.6 + 9.3 + 11.8 = 63.6 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  6. 6Maxgrow India Ltdturning · Too little evidence to rank firmly · 57% evidence63.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 23.6/35 · Revenue 100% · Profit 100% · Operating margin change -0.2 points · 71% evidenceCapital efficiency 16.2/25 · ROCE 23.5% (year to Mar 2026) · Operating margin 1.6% · 95% evidenceValuation 11.4/20 · P/E 1.1× · PEG — · 15% evidenceRelative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 100.1% · 1 year — · 25% evidence · 1 of 1 week aheadExact sum: 23.6 + 16.2 + 11.4 + 12.3 = 63.5 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  7. 7Arisinfra Solutions LtdARIS · breaking out · Evidence leans up · 60% evidence63.2out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 27.7/35 · Revenue 41.7% · Profit 100% · Operating margin change 3 points · 95% evidenceCapital efficiency 13.8/25 · ROCE 15.6% (year to Mar 2026) · Operating margin 11.7% · 76% evidenceValuation 10.5/20 · P/E 16.4× · PEG — · 15% evidenceRelative strength 11.2/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 13.6% · 1 year -3.6% · 25% evidence · 11 of 12 weeks aheadExact sum: 27.7 + 13.8 + 10.5 + 11.2 = 63.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  8. 8SG Mart LtdSGMART · leader · Evidence leans up · 83% evidence61.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 22.0/35 · Revenue 9.7% · Profit 26.7% · Operating margin change 3 points · 100% evidenceCapital efficiency 11.6/25 · ROCE 10.2% (year to Mar 2026) · Operating margin 4.6% · 100% evidenceValuation 9.3/20 · P/E 85.2× · PEG — · 15% evidenceRelative strength 18.4/20 · Strength vs its industry (price vs its 52-week average, weekly) 43.2% · Strength vs NIFTY 500 (same reading) 56.8% · 1 year 194.2% · 100% evidence · 12 of 12 weeks aheadExact sum: 22 + 11.6 + 9.3 + 18.4 = 61.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  9. 9Dhunseri Ventures LtdDVL · breaking out · Evidence leans up · 74% evidence61.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 21.8/35 · Revenue 21.4% · Profit 100% · Operating margin change 82 points · 71% evidenceCapital efficiency 11.1/25 · ROCE 6.7% (year to Mar 2026) · Operating margin 23.1% · 76% evidenceValuation 12.8/20 · P/E 3.6× · PEG — · 50% evidenceRelative strength 15.6/20 · Strength vs its industry (price vs its 52-week average, weekly) 1.5% · Strength vs NIFTY 500 (same reading) 14.8% · 1 year 5.4% · 100% evidence · 12 of 12 weeks aheadExact sum: 21.8 + 11.1 + 12.8 + 15.6 = 61.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  10. 10DC Infotech & Communication LtdDCI · quiet · Evidence leans up · 75% evidence61.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 22.9/35 · Revenue 33.9% · Profit 37.6% · Operating margin change -0.3 points · 100% evidenceCapital efficiency 16.6/25 · ROCE 23% (year to Mar 2026) · Operating margin 5.2% · 100% evidenceValuation 10.4/20 · P/E 23.5× · PEG — · 50% evidenceRelative strength 11.1/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 12.1% · 1 year — · 25% evidence · 6 of 8 weeks aheadExact sum: 22.9 + 16.6 + 10.4 + 11.1 = 61 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  11. 11Singer India LtdSINGERIND · breaking out · Evidence leans up · 68% evidence59.9out of 100GrowthCapitalValuationRelative
  12. 12Ivalue Infosolutions LtdIVALUE · quiet · Evidence leans up · 78% evidence58.3out of 100GrowthCapitalValuationRelative
  13. 13Aayush Art and Bullion Ltdleader · Too little evidence to rank firmly · 59% evidence58.0out of 100GrowthCapitalValuationRelative
  14. 14Vision Infra Equipment Solutions LtdVIESL · losing its lead · Too little evidence to rank firmly · 60% evidence57.6out of 100GrowthCapitalValuationRelative
  15. 15Patel Retail LtdPATELRMART · breaking out · Evidence leans up · 68% evidence57.3out of 100GrowthCapitalValuationRelative
  16. 16Tembo Global Industries LtdTEMBO · quiet · Evidence leans up · 71% evidence57.2out of 100GrowthCapitalValuationRelative
  17. 17Euro Pratik Sales LtdEUROPRATIK · basing · Evidence leans up · 68% evidence55.2out of 100GrowthCapitalValuationRelative
  18. 18Prostarm Info Systems LtdPROSTARM · quiet · Evidence leans up · 68% evidence54.7out of 100GrowthCapitalValuationRelative
  19. 19Mardia Samyoung Capillary Tubes Company LtdMSCTC · Evidence leans up · 60% evidence52.5out of 100GrowthCapitalValuationRelative
  20. 20BMW Ventures LtdBMW · breaking out · Evidence leans up · 60% evidence51.7out of 100GrowthCapitalValuationRelative
  21. 21MMTC LtdMMTC · quiet · Evidence leans up · 86% evidence50.9out of 100GrowthCapitalValuationRelative
  22. 22Transchem LtdTRANSCHEM · turning · Evidence leans up · 60% evidence50.8out of 100GrowthCapitalValuationRelative
  23. 23Shiv Aum Steels LtdSHIVAUM · breaking out · Evidence leans up · 67% evidence50.6out of 100GrowthCapitalValuationRelative
  24. 24Cropster Agro LtdCROPSTER · Evidence leans down · 60% evidence49.6out of 100GrowthCapitalValuationRelative
  25. 25Sudarshan Pharma Industries Ltdquiet · Evidence leans down · 87% evidence48.8out of 100GrowthCapitalValuationRelative
  26. 26Hexa Tradex LtdHEXATRADEX · quiet · Evidence leans down · 74% evidence44.9out of 100GrowthCapitalValuationRelative
  27. 27Adani Enterprises LtdADANIENT · quiet · Evidence leans down · 93% evidence44.5out of 100GrowthCapitalValuationRelative
  28. 28A-1 LtdA1L · Evidence leans down · 60% evidence43.5out of 100GrowthCapitalValuationRelative
  29. 29Blue Pearl Agriventures LtdBPAGRI · basing · Too little evidence to rank firmly · 57% evidence43.1out of 100GrowthCapitalValuationRelative
  30. 30Lloyds Enterprises LtdLLOYDSENT · quiet · Evidence leans down · 75% evidence40.7out of 100GrowthCapitalValuationRelative
  31. 31Shanti Overseas (India) LtdSHANTI · Evidence leans down · 61% evidence39.0out of 100GrowthCapitalValuationRelative
  32. 32Riddhi Siddhi Gluco Biols Ltdquiet · Evidence leans down · 87% evidence37.5out of 100GrowthCapitalValuationRelative
  33. 33Fabtech Technologies LtdFABTECH · basing · Evidence leans down · 68% evidence37.0out of 100GrowthCapitalValuationRelative
  34. 34PTC India LtdPTC · quiet · Evidence leans down · 82% evidence35.8out of 100GrowthCapitalValuationRelative
  35. 35Uniphos Enterprises LtdUNIENTER · basing · Evidence leans down · 75% evidence35.8out of 100GrowthCapitalValuationRelative
  36. 36Hardwyn India LtdHARDWYN · quiet · Evidence leans down · 90% evidence35.7out of 100GrowthCapitalValuationRelative
  37. 37Shah Foods Ltdquiet · Too little evidence to rank firmly · 53% evidence34.5out of 100GrowthCapitalValuationRelative
  38. 38Manbro Industries LtdToo little evidence to rank firmly · 52% evidence33.3out of 100GrowthCapitalValuationRelative
  39. 39BN Agrochem LtdBNAGROCHEM · basing · Most evidence points down · 64% evidence33.2out of 100GrowthCapitalValuationRelative
  40. 40Kothari Industrial Corporation LtdKOTIC · quiet · Too little evidence to rank firmly · 53% evidence33.2out of 100GrowthCapitalValuationRelative
  41. 41Neueon Corporation LtdNEUEON · quiet · Too little evidence to rank firmly · 56% evidence32.1out of 100GrowthCapitalValuationRelative
  42. 42Oswal Agro Mills LtdOSWALAGRO · basing · Most evidence points down · 60% evidence30.6out of 100GrowthCapitalValuationRelative
  43. 43Le Merite Exports LtdLEMERITE · Too little evidence to rank firmly · 58% evidence26.7out of 100GrowthCapitalValuationRelative
  44. 44Yogi LtdYOGI · turning · Most evidence points down · 70% evidence24.9out of 100GrowthCapitalValuationRelative
  45. 45Pervasive Commodities Ltdbreaking out · Too little evidence to rank firmly · 47% evidence64.5out of 100GrowthCapitalValuationRelative
  46. 46Magnus Steel & Infra LtdToo little evidence to rank firmly · 40% evidence61.2out of 100GrowthCapitalValuationRelative
  47. 47Susan Electricals India LtdToo little evidence to rank firmly · 36% evidence60.0out of 100GrowthCapitalValuationRelative
  48. 48Q-Line Biotech LtdQLINE · quiet · Too little evidence to rank firmly · 31% evidence59.7out of 100GrowthCapitalValuationRelative
  49. 49Bizotic Commercial LtdBIZOTIC · quiet · Too little evidence to rank firmly · 38% evidence59.5out of 100GrowthCapitalValuationRelative
  50. 50Pramara Promotions LtdPRAMARA · Too little evidence to rank firmly · 42% evidence58.6out of 100GrowthCapitalValuationRelative
  51. 51HP Telecom India LtdHPTL · turning · Too little evidence to rank firmly · 43% evidence58.2out of 100GrowthCapitalValuationRelative
  52. 52Aptus Pharma Ltdturning · Too little evidence to rank firmly · 41% evidence55.4out of 100GrowthCapitalValuationRelative
  53. 53Proventus Agrocom LtdPROV · breaking out · Too little evidence to rank firmly · 50% evidence55.1out of 100GrowthCapitalValuationRelative
  54. 54SK Minerals & Additives Ltdquiet · Too little evidence to rank firmly · 45% evidence53.6out of 100GrowthCapitalValuationRelative
  55. 55Monika Alcobev LtdMONIKA · Too little evidence to rank firmly · 22% evidence52.4out of 100GrowthCapitalValuationRelative
  56. 56State Trading Corporation of India LtdSTCINDIA · basing · Too little evidence to rank firmly · 47% evidence50.7out of 100GrowthCapitalValuationRelative
  57. 57AUDROC LtdToo little evidence to rank firmly · 43% evidence47.1out of 100GrowthCapitalValuationRelative
  58. 58Onix Solar Energy LtdONIXSOLAR · quiet · Too little evidence to rank firmly · 47% evidence46.3out of 100GrowthCapitalValuationRelative
  59. 59Arvaya Healthcare Ltd this pageARVAYA · turning · Too little evidence to rank firmly · 46% evidence45.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 19.5/35 · Revenue -47.4% · Profit -80% · Operating margin change 46.1 points · 62% evidenceCapital efficiency 3.9/25 · ROCE -3.8% (year to Mar 2026) · Operating margin -810% · 76% evidenceValuation 10.0/20 · P/E — · PEG — · 0% evidenceRelative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 48.2% · 1 year — · 25% evidence · 2 of 7 weeks aheadExact sum: 19.5 + 3.9 + 10 + 11.9 = 45.3 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  60. 60C K K Retail Mart LtdCKKRETAIL · Too little evidence to rank firmly · 36% evidence45.3out of 100GrowthCapitalValuationRelative
  61. 61Prabhatam Infra Venture Ltdturning · Too little evidence to rank firmly · 27% evidence45.1out of 100GrowthCapitalValuationRelative
  62. 62Satani Bearings Ltdbreaking out · Too little evidence to rank firmly · 43% evidence43.0out of 100GrowthCapitalValuationRelative
  63. 63Keto Motors Ltdquiet · Too little evidence to rank firmly · 43% evidence39.8out of 100GrowthCapitalValuationRelative
  64. 64Aerpace Industries Ltdbreaking out · Too little evidence to rank firmly · 36% evidence38.4out of 100GrowthCapitalValuationRelative
  65. 65RRP Semiconductor LtdRRP · Too little evidence to rank firmly · 47% evidence35.6out of 100GrowthCapitalValuationRelative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Trading, all 65 compared on one page.

Which companies are close to Arvaya Healthcare in size?

Arvaya Healthcare is the 49th largest of 61 Trading companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Transchem, Mardia Samyoung Capillary Tubes Company and SK Minerals & Additives. Just below it: Riddhi Siddhi Gluco Biols, Oswal Agro Mills and Blue Pearl Agriventures.

Trading companies close in size

  1. Transchem Ltd ₹503 crore
  2. Mardia Samyoung Capillary Tubes Company Ltd ₹503 crore
  3. SK Minerals & Additives Ltd ₹497 crore
  4. Arvaya Healthcare Ltd ₹488 crore
  5. Riddhi Siddhi Gluco Biols Ltd ₹482 crore
  6. Oswal Agro Mills Ltd ₹468 crore
  7. Blue Pearl Agriventures Ltd ₹465 crore

All 61 Trading companies, largest first

Companies close in size in other industries

  1. Omax Autos Ltd ₹488 crore · Auto Ancillaries - Sheet Metal
  2. Shriram Asset Management Co Ltd ₹488 crore
  3. Arvaya Healthcare Ltd ₹488 crore
  4. Aptech Ltd ₹488 crore · Computer Education
  5. Credo Brands Marketing Ltd ₹488 crore · Textiles - Readymade Apparel

What else do people ask about Arvaya Healthcare?

What were Arvaya Healthcare's latest quarterly results?

Arvaya Healthcare Ltd reported revenue of ₹0.1 Cr and a net loss of ₹0.9 Cr for the Jun 2026 quarter. Earnings per share were −₹0.19. The operating margin was −810.0% (as of 17 November 2026).

What is Arvaya Healthcare's market cap?

Arvaya Healthcare Ltd's market capitalisation is ₹488 Cr at a share price of ₹101.65. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 17 November 2026).

How is Arvaya Healthcare performing?

Arvaya Healthcare Ltd's share price has been rising for 61 weeks. Over the past 13 weeks it has done worse than the NIFTY 500, for 4 weeks running. This describes what the data did, not a rating (as of 17 November 2026).

Will Arvaya Healthcare's share price go up?

This page does not forecast Arvaya Healthcare Ltd's share price. What it shows instead: the share price is ₹101.65, and it has been rising for 61 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 17 November 2026).

Who owns Arvaya Healthcare?

Promoters own 28.3% of Arvaya Healthcare Ltd, foreign institutions —, domestic institutions, and the public 71.7% (latest quarter). The biggest change over the last two years: Promoters raised their stake by 20.6 percentage points over 8 quarters (as of 17 November 2026).

Where is Arvaya Healthcare in its business cycle?

Arvaya Healthcare Ltd's FY26 operating margin was 8.0%, against a 12-year range of −185.7% to 8.0%. The latest quarter was −810.0%, below the bottom of its own yearly range in the latest quarter, a low point in its cycle.

Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 17 November 2026).

What could break the Arvaya Healthcare story?

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high.

On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 17 November 2026).

Is Arvaya Healthcare a stock worth studying right now?

What the numbers show: Arvaya Healthcare Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results.

Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 17 November 2026).

Where do these numbers come from?

Sector Alpha, written by code from the published numbers. Data as of 17 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.

More lists

Every Sector Alpha list, grouped

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.